IPW
BMRN icon

IronBridge Private Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

IronBridge Private Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-51,961
Closed -$4.59M – 64
2021
Q4 		$4.59M Buy
+51,961
New +$4.29M 2.39% 21

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

IronBridge Private Wealth's BMRN Position: Q1 2022 in Review

IronBridge Private Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2022, closing a stake of 51,961 shares — an estimated $4.59M sold.

IronBridge Private Wealth first reported a position in BMRN in Q4 2021 and held it in 1 quarter. The position peaked at $4.59M in Q4 2021. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

  • IronBridge Private Wealth reported no remaining BioMarin Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • IronBridge Private Wealth sold 51,961 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $4.59M.
  • IronBridge Private Wealth first reported a position in BioMarin Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • IronBridge Private Wealth's BioMarin Pharmaceuticals position peaked at $4.59M in Q4 2021.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on IronBridge Private Wealth's 13F filing for Q1 2022, filed 16 May 2022.